Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc (VOR) is a clinical-stage biotechnology pioneer developing engineered hematopoietic stem cell (eHSC) therapies for hematological cancers. This page serves as the definitive source for verified corporate announcements, clinical trial updates, and strategic developments related to their innovative platform.
Investors and researchers will find timely updates on key milestones including trial progress, regulatory filings, and partnership announcements. All content is curated to provide actionable insights into the company’s novel approach to protecting healthy cells during cancer treatments while enabling targeted tumor eradication.
The resource features press releases covering financial results, manufacturing advancements, and peer-reviewed research publications. Scientific updates detail progress in their eHSC platform’s applications for CAR-T therapies and antigen-targeted treatment regimens.
Bookmark this page for streamlined access to Vor Biopharma’s latest developments in cell engineering and hematological oncology research. Regularly updated to reflect new data presentations, clinical collaborations, and pipeline expansions.
Vor Biopharma (Nasdaq: VOR) reported Q2 2021 financial results, highlighting advancements in its clinical trials and collaborations. The company expects to enroll the first patient in its VOR33 acute myeloid leukemia (AML) Phase 1/2a trial shortly and aims to report initial clinical data by mid-2022. Vor has entered partnerships with Abound Bio and Janssen to enhance treatment options. Additionally, they initiated the build-out of an in-house clinical manufacturing facility, maintaining a robust cash position of $244.6 million to support operations into Q1 2023.
Vor Biopharma announced a collaboration with Janssen Biotech to investigate the combination of Vor’s engineered hematopoietic stem cell (eHSC) platform with Janssen’s bi-specific antibodies for treating acute myeloid leukemia (AML). This partnership aims to leverage the strengths of both technologies, enhancing treatment potential while minimizing off-target effects. Each company retains rights to their respective technologies, marking a significant step in Vor's strategy to explore advanced treatment options for blood cancer patients.
Vor Biopharma (Nasdaq: VOR) announced plans to establish an in-house clinical manufacturing facility in Cambridge, Massachusetts, to support its engineered hematopoietic stem cell (eHSC) and CAR-T therapy candidates. Expected to begin operations in 2022, this facility aims to enhance oversight of drug product manufacturing for clinical trials while complying with cGMP standards. The initiative aligns with Vor's strategic goals and will not impact its cash runway, which is projected to sustain operations through Q1 2023. The company also plans to hire more employees to support these operations.
Vor Biopharma (Nasdaq: VOR) has appointed Matthew R. Patterson as Chairman of its Board of Directors, bringing nearly 30 years of biotechnology leadership experience. Patterson previously co-founded and led Audentes Therapeutics. Tania Philipp has been promoted to Chief People Officer, enhancing Vor's focus on building an expert team in cell therapy.
The company aims to innovate cancer treatment through engineered hematopoietic stem cell (eHSC) therapies, which offer treatment-resistant options to enhance targeted therapies.
Vor Biopharma (Nasdaq: VOR) and Abound Bio have entered a strategic collaboration to develop CAR-T treatments combined with Vor's engineered hematopoietic stem cell (eHSC) platform, focused on treating acute myeloid leukemia (AML) and other blood cancers. The partnership aims to enhance multi-targeted CAR-T therapies while protecting healthy cells, aligning with Vor's mission of creating effective cancer treatments. Financial terms of the collaboration were not disclosed.
Vor Biopharma, a pioneering cell therapy company, announced that its President, Robert Ang, and CFO, Nathan Jorgensen, will present at two key conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 4:00 PM ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 9:40 AM ET. These presentations will showcase Vor's innovative engineered hematopoietic stem cell therapies aimed at treating cancer. Live webcasts will be available on the company's website.
Vor Biopharma (Nasdaq: VOR) announced the clearance of its clinical trial application (CTA) for VOR33 in acute myeloid leukemia (AML) by Health Canada, marking a significant regulatory milestone. The company successfully raised $203.4 million through its initial public offering (IPO), enhancing its cash position to $262.6 million as of March 31, 2021. In addition, Vor plans to present critical findings regarding VOR33 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, supporting its upcoming Phase 1/2a trial set to begin in Q2 2021.
Vor Biopharma (Nasdaq: VOR) announces two presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 11, 2021. The presentations will focus on VOR33, an engineered hematopoietic stem cell (eHSC) clinical candidate targeting acute myeloid leukemia. The oral presentation by Dr. John Lydeard will detail the CRISPR/Cas9 technology used in VOR33, while a poster will assess off-target editing. These developments aim to enhance treatment efficacy and patient outcomes.
Vor Biopharma (Nasdaq: VOR) announced that the FDA accepted the IND for VOR33, its lead eHSC product candidate targeting acute myeloid leukemia (AML). The company successfully completed an IPO, raising $203.4 million, enhancing its financial standing. Cash at year-end 2020 was $48.5 million, with R&D expenses rising to $31.6 million due to increased preclinical studies. Vor reported a net loss of $43.3 million for 2020. Upcoming milestones include the initiation of the Phase 1/2a trial for VOR33 in Q2 2021 and initial data expected in late 2021 or early 2022.
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell therapies, announced its participation in the Barclays Global Healthcare Conference, set for March 9-11, 2021. CEO Robert Ang and CFO Nathan Jorgensen will present on March 11 at 3:00 p.m. E.T. Interested parties can access the live webcast through the Investors section of Vor's website. Vor Biopharma is dedicated to innovating cancer treatments, focusing on creating treatment-resistant transplants that enhance targeted therapies while protecting healthy cells.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
